In addition, ECGC showed therapeutic potential in obesity inhibiting white and beige 3T3-L1 and D12 preadipocyte growth by upregulated miR-let-7a and subsequent high-mobility group AT-hook 2 (HMGA2) suppression [98] and inhibiting the MAPK7 pathway by increased miR-143 levels [99]. The gene discussed is HMGA2; the disease is Obesity.